News | May 23, 2012

Promus Element Stent Demonstrates Long-Term Safety, Effectiveness in PLATINUM Small Vessel Study

Two-Year Clinical Data Demonstrate Low Adverse Event Rates, Including No Myocardial Infarction or Stent Thrombosis

May 23, 2012 — Boston Scientific Corp. announced two-year results from the PLATINUM Small Vessel study, demonstrating excellent safety and effectiveness outcomes for the 2.25 mm Promus Element everolimus-eluting platinum chromium (PtCr) stent system in treating de novo coronary lesions in small coronary vessels. Analysis of the data was presented at EuroPCR 2012 in Paris.

"The PLATINUM Small Vessel data continue to demonstrate very low revascularization rates, with no myocardial infarction or stent thrombosis through two years of follow-up in patients treated with the 2.25 mm Promus Element stent," said Ian Meredith, professor and director of MonashHeart, at Monash Medical Centre in Melbourne, Australia, and co-principal investigator for the PLATINUM clinical program. "These long-term results are impressive, especially considering the small vessel diameters that were evaluated in this study."

The PLATINUM Small Vessel study previously met its primary endpoint of target lesion failure (TLF) at 12 months with a rate of 2.4 percent for the Promus Element stent compared to a pre-specified performance goal of 21.1 percent (p<0.001), based on historical outcomes for the 2.25 mm Taxus Express paclitaxel-eluting stent. The TLF rate at two years for the Promus Element was 4.7 percent while the rate of target lesion revascularization (TLR) was 2.5 percent. Rates of other major adverse events remained low in patients treated with study stents at two years, including cardiac death (2.3 percent), myocardial infarction (0.0 percent) and Academic Research Consortium (ARC)-defined definite/probable stent thrombosis (0.0 percent). There were no deaths between one and two years for patients treated with the Promus Element stent.

"The PLATINUM Small Vessel data build on the positive long-term outcomes from the PLATINUM Workhorse trial, which reported excellent safety and effectiveness of the Promus Element stent in workhorse lesions and demonstrated superior efficacy compared to the Xience V (Promus) Stent in a landmark analysis of revascularization outcomes from year one to year two," said Keith D. Dawkins, M.D., global chief medical officer for Boston Scientific. "The results demonstrate a highly effective platinum chromium small vessel stent platform with an excellent safety profile. This study of the 2.25 mm Promus Element Stent reconfirms our commitment to providing a complete range of stenting solutions and sizes for physicians and their patients."

Boston Scientific received CE mark approval for the Promus Element stent system in 2009 and for the Promus Element Plus stent system in 2011. In the United States, the Promus Element Plus stent system was approved by the U.S. Food and Drug Administration (FDA) in 2011. The Promus Element Stent, part of the Promus Element stent system and the Promus Element Plus stent system, employs a proprietary PtCr alloy designed specifically for coronary stenting, which enables enhanced visibility, less recoil, excellent conformability and higher radial strength. The Promus Element Plus stent system employs an advanced low-profile delivery system, designed to facilitate precise delivery of the stent across challenging lesions.

Xience is a trademark of the Abbott Laboratories group of companies. Promus is a private-labeled Xience V everolimus-eluting stent system manufactured by Abbott and distributed by Boston Scientific.

For more information:

Related Content

Patient Enrollment Completed in U.S. IDE Study of THERMOCOOL SMARTTOUCH SF Catheter
News | Clinical Study | March 15, 2018
March 15, 2018 –  Johnson & Johnson Medical Devices Companies announced today that Biosense Webster, Inc., who wo
Lexington Begins HeartSentry Clinical Trial
News | Clinical Study | February 20, 2018
February 20, 2018 – Lexington Biosciences, Inc., a development-stage medical device company, announced the commenceme
Endologix Completes Patient Enrollment in the ELEVATE IDE Clinical Study
News | Clinical Study | February 06, 2018
February 6, 2018 – Endologix, a developer and marketer of treatments for aortic disorders, announced the completion o
12-Month Results from Veryan Medical's MIMICS-2 IDE Study Presented at LINC
News | Clinical Study | February 01, 2018
February 1, 2018 – Thomas Zeller (Bad Krozingen, Germany) presented the 12-month results from Veryan Medical’s MIMICS
LimFlow Completes U.S. Feasibility Study Enrollment, Receives FDA Device Status
News | Clinical Study | February 01, 2018
February 1, 2018 –  LimFlow SA, developer of minimally-inv
ESC 2017 late breaking trial hot line study presentations.
News | Clinical Study | September 12, 2017
September 12, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking C
U.K., NHS studies, weekend effect, hospital admission, atrial fibrillation, heart failure
News | Clinical Study | June 28, 2016
New research shows patients admitted to National Health Service (NHS) hospitals in the United Kingdom for atrial...
stroke risk
News | Clinical Study | August 28, 2015
Most people assume strokes only happen to octogenarians, but recent evidence suggests that survivors of childhood can
Overlay Init